Comparison |
| NDC Number |
49702024015 | 49702025315 |
| Strength |
600 mg - 900 mg | 400 mg - 600 mg |
| Volume |
3 mL - 3 mL | 2 mL - 2 mL |
| Application |
HIV Integrase Inhibitor and HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor | HIV Integrase Inhibitor and HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor |
| Container Type |
Single-Dose Kit | Single-Dose Kit |
| Country of Origin |
Unknown | Unknown |
| Dosage Form |
Injection | Injection |
| Generic Drug Name |
Cabotegravir / Rilpivirine | Cabotegravir / Rilpivirine |
| Product Dating |
McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days |
| Storage Requirements |
Requires Refrigeration | Requires Refrigeration |
| Type |
Intramuscular | Intramuscular |
| UNSPSC Code |
51343800 | 51343800 |
| Features and Benefits |
- CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
- Requires Refrigeration
- Intramuscular (IM) gluteal
|
- CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
- Requires Refrigeration
- Intramuscular (IM) gluteal
|
